Rapid Malaria Test Evaluated In Different Locales
|
By LabMedica International staff writers Posted on 20 Jun 2013 |

Image: VIKIA Malaria rapid diagnostic test (Photo courtesy of IMAccess).
A recently introduced malaria rapid diagnostic test (RDT) has been evaluated in an area endemic for the disease in Africa and in a nonendemic setting in Europe.
The RDTs are a useful tool in endemic malaria countries, where light microscopy is not feasible and in nonendemic countries where they can be used as complementary tests to provide timely results in case of microscopy inexperience.
Scientists at the Hospices Civils de Lyon (France) working with colleagues in Mali, tested blood samples that were collected during a 12-months and six-months period in 2011 from patients suspected to have malaria in Lyon and Bamako, respectively. Samples of 877 patients from both sites were included in the study.
The samples were examined by light microscopy, the VIKIA Malaria Ag Pf/Pan RDT (IMAccess; Lyon, France) and in Bamako additionally with the CareStart RDT (AccessBio, Somerset, NJ, USA). All discordant results between microscopy and the two RDTs were resolved by a real time polymerase chain reaction (PCR) and test characteristics were recalculated according to the PCR-corrected results. Sensitivity, specificity, positive predictive value, and negative predictive value were used to evaluate test performance.
The VIKIA Malaria Ag Pf/Pan RDT is an immunochromatographic test in which monoclonal antibodies target the histidine-rich protein II (HRP-II) protein antigen specific to Plasmodium falciparum and the Pan Aldolase antigen, common to all the Plasmodium species. This RDT had sensitivity for Plasmodium falciparum of 98% in Lyon and 96% in Bamako, and its performance was similar to PCR-corrected microscopy. No significant difference in the detection of falciparum and non-falciparum malaria between the two RDTs was observed. The performance of the VIKIA RDT was not significantly different for P. falciparum and non-falciparum species compared to PCR-corrected microscopy method.
The authors concluded that the VIKIA Malaria Ag Pf/Pan showed a similar level of performance to comparative RDTs in endemic and in nonendemic settings. Community health workers were as efficient as medical students in managing malaria cases using both RDTs tested. This RDT, which has recently become commercially available, could be used to implement efficient malaria diagnosis in low-income endemic countries or complement PCR/microscopy diagnosis in nonendemic regions. The study was published on June 6, 2013, in the Malaria Journal.
Related Links:
Hospices Civils de Lyon
IMAccess
AccessBio
The RDTs are a useful tool in endemic malaria countries, where light microscopy is not feasible and in nonendemic countries where they can be used as complementary tests to provide timely results in case of microscopy inexperience.
Scientists at the Hospices Civils de Lyon (France) working with colleagues in Mali, tested blood samples that were collected during a 12-months and six-months period in 2011 from patients suspected to have malaria in Lyon and Bamako, respectively. Samples of 877 patients from both sites were included in the study.
The samples were examined by light microscopy, the VIKIA Malaria Ag Pf/Pan RDT (IMAccess; Lyon, France) and in Bamako additionally with the CareStart RDT (AccessBio, Somerset, NJ, USA). All discordant results between microscopy and the two RDTs were resolved by a real time polymerase chain reaction (PCR) and test characteristics were recalculated according to the PCR-corrected results. Sensitivity, specificity, positive predictive value, and negative predictive value were used to evaluate test performance.
The VIKIA Malaria Ag Pf/Pan RDT is an immunochromatographic test in which monoclonal antibodies target the histidine-rich protein II (HRP-II) protein antigen specific to Plasmodium falciparum and the Pan Aldolase antigen, common to all the Plasmodium species. This RDT had sensitivity for Plasmodium falciparum of 98% in Lyon and 96% in Bamako, and its performance was similar to PCR-corrected microscopy. No significant difference in the detection of falciparum and non-falciparum malaria between the two RDTs was observed. The performance of the VIKIA RDT was not significantly different for P. falciparum and non-falciparum species compared to PCR-corrected microscopy method.
The authors concluded that the VIKIA Malaria Ag Pf/Pan showed a similar level of performance to comparative RDTs in endemic and in nonendemic settings. Community health workers were as efficient as medical students in managing malaria cases using both RDTs tested. This RDT, which has recently become commercially available, could be used to implement efficient malaria diagnosis in low-income endemic countries or complement PCR/microscopy diagnosis in nonendemic regions. The study was published on June 6, 2013, in the Malaria Journal.
Related Links:
Hospices Civils de Lyon
IMAccess
AccessBio
Latest Microbiology News
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
- Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
- Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
- Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
- Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







